大麻素拮抗剂SR 141716后的食欲抑制与体重减轻
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.
作者信息
Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa G L
机构信息
C.N.R. Center for Neuropharmacology, Bernard B. Brodie Department of Neuroscience, University of Cagliari, Italy.
出版信息
Life Sci. 1998;63(8):PL113-7. doi: 10.1016/s0024-3205(98)00322-1.
The effect of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight was assessed in adult, non-obese Wistar rats. The daily administration of SR 141716 (2.5 and 10 mg/kg; i.p.) reduced dose-dependently both food intake and body weight. Tolerance to the anorectic effect developed within 5 days; in contrast, body weight in SR 141716-treated rats remained markedly below that of vehicle-treated rats throughout the entire treatment period (14 days). The results suggest that brain cannabinoid receptors are involved in the regulation of appetite and body weight.
在成年非肥胖Wistar大鼠中评估了大麻素CB1受体拮抗剂SR 141716对食物摄入量和体重的影响。每日腹腔注射SR 141716（2.5和10毫克/千克）可剂量依赖性地降低食物摄入量和体重。5天内对食欲抑制作用产生了耐受性；相比之下，在整个治疗期（14天）内，接受SR 141716治疗的大鼠体重仍明显低于接受赋形剂治疗的大鼠。结果表明，脑内大麻素受体参与食欲和体重的调节。
Zotero 插件